Merck Enters Collaboration and Option to License Agreement with Nerviano Medical Sciences to Develop Next-Generation PARP1 Selective Inhibitor
NMS-293 is a next generation, orally available, brain-penetrant PARP1 selective inhibitor NMS-293 is currently studied in Phase I as monotherapy for the treatment of patients with BRCA-mutated t......